USCarePharm Co., Ltd., a leader in natural material-based R&D, announced its recent presentation of new research on vascular health functional ingredients at the Annual Conference of the Korean Society of Pharmacognosy. During the academic forum, USCarePharm unveiled the results of its advanced research into plant-derived bioactive compounds that demonstrated efficacy in supporting vascular wall integrity and circulatory health. The study focused on a newly identified material, USCP0112, which showed promise in improving endothelial function, reducing oxidative stress, and modulating lipid metabolism — all crucial factors in vascular wellness. This achievement is part of USCarePharm’s broader UMAP Tech™ platform, which specializes in the systematic discovery, screening, and optimization of high-performance natural ingredients for use in pharmaceuticals, functional foods, and cosmeceuticals. “The results we shared reflect years of targeted research in functional ingredients derived from traditional medicinal plants,” said CEO Song Seok-jin. “We are committed to transforming these findings into clinically meaningful applications that promote cardiovascular wellness and overall health.” The presentation further strengthens USCarePharm’s reputation as a pioneer in bio-convergent healthcare innovation, capable of bridging the gap between traditional natural remedies and scientifically validated modern therapeutics. USCarePharm plans to continue collaboration with academic institutions and industry partners to accelerate the commercialization of science-based natural health solutions.

2025.07.28 14:10

USCarePharm Co., Ltd., a leading innovator in bio-based functional ingredients, will unveil its latest research on vascular anti-aging and health-supporting materials at the 53rd Annual General Meeting & Scientific Conference of the Korean Society of Pharmacognosy, to be held on November 3–4 at Ewha Womans University ECC. The company will present preclinical study results on USCP-GHV-014, a proprietary natural material demonstrating significant efficacy in reducing intimal-medial thickness (IMT) and inhibiting collagen deposition in blood vessels. The findings suggest preserved vascular elasticity and reduced pulse pressure, both crucial indicators for cardiovascular health. As vascular aging begins as early as in the 20s, structural stiffening of arterial walls and loss of elasticity increase pulse pressure — the difference between systolic and diastolic blood pressure. This pressure widening is a strong predictor of cardiovascular risk. Given the rise in vascular-related concerns among younger populations due to high-fat diets, sedentary lifestyles, and chronic stress, proactive vascular care has become essential across all age groups. “We are proud to present the promising preclinical data of USCP-GHV-014 in preventing vascular aging at this prestigious conference,” said CEO Song Seok-jin of USCarePharm. “Following successful human application trials, we aim to open a new frontier in the vascular wellness market with scientifically validated and systematically developed natural health ingredients.” USCP-GHV-014 is being developed under the High Value-Added Food Technology Development Program, supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry (IPET). The company is also pursuing intellectual property rights to protect its novel formulation.

2025.07.28 14:09

USCarePharm Expands R&D for Functional Pharmaceutical and Nutraceutical Ingredients Derived from Natural and Bio-Based Materials USCarePharm Co., Ltd., a specialized company in the development of high-performance functional materials, announced plans to expand its business into the development of functional pharmaceutical actives and health supplement ingredients, leveraging both natural products and bio-based technologies. Founded in 2016, USCarePharm brings together more than two decades of pharmaceutical expertise and has built a proprietary platform for developing functional materials derived from natural sources. The company has recently identified promising compounds, including USCP0107, a natural ingredient shown to alleviate functional dyspepsia by inhibiting gastric mucosal inflammation, and USCP0112, which supports vascular wall health. Both candidates are currently progressing rapidly toward commercialization. Targeting chronic digestive and vascular conditions, USCarePharm is committed to developing safe and efficacious bioactive ingredients to support the development of health functional foods and functional therapeutics. CEO Song Seok-jin commented: “We have accumulated proprietary know-how in discovering and commercializing functional materials from natural sources. Our latest bio-based ingredients have been standardized and optimized for industrial use, and we are poised to scale up commercialization. We also plan to strengthen collaboration with domestic and international research institutes to further advance the development of functional therapeutic foods and biopharmaceuticals.” With its solid foundation in bio-convergent R&D and natural product science, USCarePharm aims to become a key innovator in the functional healthcare sector. Source: IBabyNews © IBabyNews. Unauthorized reproduction or redistribution is strictly prohibited.

2025.03.28 11:50